AzTrials
AzTrials

OsteoarthritisPhase 3NCT00809354

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

A Phase 3 study testing NSAID and tanezumab in people with Osteoarthritis and Arthritis, run by Pfizer at 333 sites in 12 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy. Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Osteoarthritis, Arthritis
What is being tested?
NSAID and tanezumab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2,720 participants
Where
333 sitesin 12 countries
Study dates
12 Feb 2009to 12 Jan 2011
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Osteoarthritis of the knee or hip according to ACR criteria with Kellgren-Lawrence x-ray grade equal to, or greater than, 2.
  • Patients must be experiencing some benefit from their current stable dose regimen of oral NSAID therapy of either naproxen 500-1000 mg/day or celecoxib 200 mg/day (either 100 mg BID or 200 mg QD) and be tolerating their NSAID regimen.
  • Pain level and function levels as required by the protocol at Screening and Baseline.
  • Willing to discontinue all non-study pain medications for osteoarthritis except rescue medication (acetaminophen) and not use prohibited pain medications throughout the duration of the study except as permitted per protocol.
  • Willing and able to comply with lifestyle guidelines, scheduled visits, treatment plan, laboratory tests and other study procedures.

Who cannot join

  • Pregnant women.
  • BMI greater than 39.
  • Fibromyalgia, regional pain caused by lumbar or cervical compression with radiculopathy or other moderate to sever pain that may confound assessments or self-evaluation of the pain associated with OA.
  • Signs and symptoms of clinically significant cardiac disease with 6 months prior to screening.
  • Diagnosis of TIA within 6 months prior to screening or diagnosis of stroke with residual deficits that would preclude completion of required study activities.
  • History, diagnosis, signs or symptoms of clinically significant neurological and/or psychiatric disease/disorder.
Show all 9Show fewer
  • At Screening: uncontrolled hypertension, hemoglobin A1c greater than or equal to 10%, ALT or AST greater than or equal to 3X upper limit of normal, creatinine exceeding 1.7 mg/dL (men) or 1.5 mg/dL (women).
  • Patients on warfarin or other coumadin anticoagulant therapy and/or lithium therapy within 30 days prior to screening.
  • Known hypersensitivity to NSAIDs or cyclooxygenase inhibitors.

Trial locations and contacts

333 sites in 12 countries.

333 sites in 12 countries

United States250 sites
  • Abilene Arthritis Center

    Abilene, Texas, 79601

  • Daystar Clinical Research, Inc.

    Akron, Ohio, 44313

  • The Center for Rheumatology, LLP

    Albany, New York, 12206

  • Blair Orthopedics Associates

    Altoona, Pennsylvania, 16602

  • Advanced Clinical Research Institute

    Anaheim, California, 92801

  • Orange County Clinical Trials, Inc.

    Anaheim, California, 92801

  • Perimeter Institute for Clinical Reseach, Inc.

    Atlanta, Georgia, 30338

  • Laureate Clinical Research Group

    Atlanta, Georgia, 30342

  • Tekton Research, Inc.

    Austin, Texas, 78745

  • Dr. Paul K. Pickrell (Physician's Office)

    Austin, Texas, 78746

  • Arthritis and Rheumatic Disease Specialties

    Aventura, Florida, 33180

  • International Physicans Research

    Aventura, Florida, 33180

  • Surgery Center of Aventura

    Aventura, Florida, 33180

  • American Health Network of Indiana, LLC

    Avon, Indiana, 46123

  • Gulf Coast Research, LLC

    Baton Rouge, Louisiana, 70808

  • The Bone and Joint Clinic

    Baton Rouge, Louisiana, 70808

  • Northwest Clinical Research Center

    Bellevue, Washington, 98007

  • Bend Memorial Clinic

    Bend, Oregon, 97701

  • Bend Memorial Clinic

    Bend, Oregon, 97702

  • The Center for Clinical Trials

    Biloxi, Mississippi, 39531

  • Quest Research Institute

    Bingham Farms, Michigan, 48025

  • Rheumatology Associates, P.C.

    Birmingham, Alabama, 35205

  • Radiant Research

    Birmingham, Alabama, 35209

  • Alliance Clinical Research

    Birmingham, Alabama, 35215

  • Shades Mountain Imaging

    Birmingham, Alabama, 35216

  • HeartCare

    Bradenton, Florida, 34202

  • Joao MA Nascimento, MD

    Bridgeport, Connecticut, 06606

  • Beacon Clinical Research

    Brockton, Massachusetts, 02301

  • Arthritis and Osteoporosis Associates of Brooklyn Heights

    Brooklyn, New York, 11201

  • Med Center

    Carmichael, California, 95608

  • Radiant Research - Phoenix Southeast

    Chandler, Arizona, 85225

  • Rehabilitation Institute of Chicago

    Chicago, Illinois, 60611

  • eStudySite

    Chula Vista, California, 91911

  • New Horizons Clinical Research

    Cincinnati, Ohio, 45242

  • Doctor's Urgent Care Offices

    Cincinnati, Ohio, 45246

  • Sterling Research Group

    Cincinnati, Ohio, 45246

  • Clinical Research of West Florida, Inc.

    Clearwater, Florida, 33765

  • The Family Healthcare Center, PA

    Clinton, South Carolina, 29325

  • Colorado Springs Family Practice

    Colorado Springs, Colorado, 80909

  • Lynn Institute of the Rockies

    Colorado Springs, Colorado, 80909

  • Columbia Arthritis Center P.A.

    Columbia, South Carolina, 29204

  • Southern Orthopaedic Sports Medicine

    Columbia, South Carolina, 29204

  • Columbus Clinical Research, Inc.

    Columbus, Ohio, 43213

  • Optimed Research, LTD

    Columbus, Ohio, 43235

  • Nature Coast Clinical Research

    Crystal River, Florida, 34429

  • Homestead Clinical Research Group, P.A.

    Cutler Bay, Florida, 33189

  • Metroplex Clinical Research Center

    Dallas, Texas, 75231

  • STAT Research, Inc.

    Dayton, Ohio, 45408

  • Dayton Science Institute (DSI)

    Dayton, Ohio, 45415

  • Hometown Urgent Care and Research

    Dayton, Ohio, 45432

  • PHP - Center for Clinical Research

    Dayton, Ohio, 45439

  • Covance CRU, Inc.

    Daytona Beach, Florida, 32117

  • Robert W. Levin MD

    Dunedin, Florida, 34698

  • Anderson and Collins Clinical Research Inc.

    Edison, New Jersey, 08817

  • Central Jersey Medical Research Center

    Elizabeth, New Jersey, 07202

  • Center for Arthritis and Osteoporosis

    Elizabethtown, Kentucky, 42701

  • Colorado Arthritis Center, PC

    Englewood, Colorado, 80113

  • MediSphere Medical Research Center, LLC

    Evansville, Indiana, 47714

  • Med Investigations, Inc.

    Fair Oaks, California, 95628

  • Internal Medicine Associates

    Fargo, North Dakota, 58103

  • Lillestol Research, LLC

    Fargo, North Dakota, 58103

  • No. County Internal Medicine & Rheumatology

    Florissant, Missouri, 63031

  • Internal Medicine Associates

    Fort Myers, Florida, 33912

  • Clinical Physiology Associates, Clinical Study Center

    Fort Myers, Florida, 33916

  • Arthritis & Osteoporosis Associates, P.A.

    Freehold, New Jersey, 07728

  • Dedicated Clinical Research

    Goodyear, Arizona, 85395

  • Eclipse Clinical Research

    Green Valley, Arizona, 85614

  • Physicians East P. A.

    Greenville, North Carolina, 27834

  • Physicians East, PA

    Greenville, North Carolina, 27834

  • Radiant Research Inc

    Greer, South Carolina, 29651

  • Mark Fisher, MD, FACRUC

    Haddon Heights, New Jersey, 08035

  • Research Consultants Group

    Hialeah, Florida, 33010

  • Palm Springs Research Institute

    Hialeah, Florida, 33012

  • Clinical Trials of America, Inc

    Hickory, North Carolina, 28601

  • Piedmont Rheumatology

    Hickory, North Carolina, 28602

  • Peters Medical Research

    High Point, North Carolina, 27262

  • East-West Medical Research Institute

    Honolulu, Hawaii, 96814

  • One Step Diagnostic

    Houston, Texas, 77030

  • Accurate Clinical Research

    Houston, Texas, 77034

  • Miracle Medical Center

    Houston, Texas, 77055

  • DM Clinical Research

    Houston, Texas, 77070

  • Rheumatology Associates of North Alabama, PC

    Huntsville, Alabama, 35801

  • Saadat Ansari, MD Office

    Huntsville, Alabama, 35801

  • Institute of Arthritis Research

    Idaho Falls, Idaho, 83404

  • Arthritis Clinic

    Jackson, Tennessee, 38305

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida, 32216

  • Rheumatology PC

    Kalamazoo, Michigan, 49009

  • Dynamic Clinical Research, Inc.

    Kansas City, Missouri, 64114

  • Joan Prouty Moore

    Kansas City, Missouri, 64114

  • Orthopaedic & Occupational Medicine

    Kansas City, Missouri, 64114

  • Triwest Research

    La Mesa, California, 91942

  • Midwest Internal Medicine, PLLC

    Lake Havasu City, Arizona, 86403

  • Florida Arthritis

    Lake Mary, Florida, 32746

  • Lakewood Orthopedic Medical & Surgical Group

    Lakewood, California, 90712

  • Premier Clinical Research LLC.

    Lakewood, California, 90712

  • Justus J Fiechtner, MD

    Lansing, Michigan, 48910-8595

  • PCM Medical Services

    Lansing, Michigan, 48917

  • Rheumatology Consultants of Delaware/Delaware Arthritis

    Lewes, Delaware, 19958

  • Pain Treatment Center of the Bluegrass

    Lexington, Kentucky, 40503

  • Pasadena Pharmacy

    Lexington, Kentucky, 40503

  • Physician Research Collaboration, LLC

    Lincoln, Nebraska, 68516

  • Little Rock Diagnostic Clinic, PA

    Little Rock, Arkansas, 72205

  • Little Rock Family Practice Clinic

    Little Rock, Arkansas, 72205

  • Prohealth Partners

    Long Beach, California, 90808

  • Peak Health Medical Group, Inc.

    Los Angeles, California, 90025

  • Gill Orthopedic Center

    Lubbock, Texas, 79410

  • Robert R. King, M.D.

    Lubbock, Texas, 79410

  • Commonwealth Biomedical Research, LLC

    Madisonville, Kentucky, 42431

  • Multicare Specialists

    Madisonville, Kentucky, 42431

  • David R. Mandel, MD, Inc

    Mayfield, Ohio, 44143

  • Ramesh C. Gupta, M.D.

    Memphis, Tennessee, 38119

  • Idaho Arthritis & Osteoporosis Center, PC

    Meridian, Idaho, 83642-6356

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Mesa, Arizona, 85202

  • Pivotal Research Centers

    Mesa, Arizona, 85210

  • Southwest Rheumatology, PA

    Mesquite, Texas, 75150

  • Pharmax Research Clinic, Inc.

    Miami, Florida, 33126

  • Community Research Foundation

    Miami, Florida, 33155

  • International Research Associates, LLC

    Miami, Florida, 33183

  • Southwest Rheumatology and Research Group, LLC

    Middleburg Heights, Ohio, 44130

  • Pivotal Research Centers

    Midvale, Utah, 84047

  • Coastal Clinical Research, Inc.

    Mobile, Alabama, 36608

  • Office of Vaughn H. Mancha, Jr., MD

    Montgomery, Alabama, 36117

  • Saltzer Medical Group PA

    Nampa, Idaho, 83686

  • Jeffrey Alper MD Research

    Naples, Florida, 34102

  • Synergy Clinical Research Center

    National City, California, 91950

  • Hill Country Medical Associates

    New Braunfels, Texas, 78130

  • Neurology Clinic of Central Texas

    New Braunfels, Texas, 78130

  • NYU Hospital for Joint Diseases

    New York, New York, 10003

  • Integris Family Care of Norman

    Norman, Oklahoma, 73069

  • LION Research

    Norman, Oklahoma, 73069

  • Central Sooner Research

    Norman, Oklahoma, 73071

  • Elise Wiesner, MD

    Norman, Oklahoma, 73071

  • McBride Clinic, Inc

    Norman, Oklahoma, 73072

  • McBride Clinic

    Norman, Oklahoma, 73072

  • American Family Medicine

    Ocala, Florida, 34471

  • Renstar Medical Research

    Ocala, Florida, 34471

  • eStudySite

    Oceanside, California, 92056

  • McBride Clinic, Inc

    Oklahoma City, Oklahoma, 73013

  • Bone and Joint Hospital at St. Anthony

    Oklahoma City, Oklahoma, 73103

  • Christine Codding, MD

    Oklahoma City, Oklahoma, 73103

  • Health Research of Oklahoma

    Oklahoma City, Oklahoma, 73103

  • Mc Bride Clinic

    Oklahoma City, Oklahoma, 73103

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma, 73112

  • Associated Orthopedics, Inc.

    Oklahoma City, Oklahoma, 73119

  • Hillcrest Clinical Research

    Oklahoma City, Oklahoma, 73119

  • Olive Branch Family Medical Center

    Olive Branch, Mississippi, 38654

  • Westroads Medical Group

    Omaha, Nebraska, 68114

  • Gundersen Clinic Ltd.

    Onalaska, Wisconsin, 54650

  • Sunshine Research Center

    Opa-locka, Florida, 33054-3818

  • Arthritis Associates

    Orlando, Florida, 32804

  • Vince and Associates Clinical Research

    Overland Park, Kansas, 66211

  • Vince and Associates Clinical Research

    Overland Park, Kansas, 66212

  • MD Medical Research

    Oxon Hill, Maryland, 20745

  • Arthritis Research of Florida, Inc.

    Palm Harbor, Florida, 34684

  • Desert Medical Group Inc., Desert Oasis Healthcare

    Palm Springs, California, 92262

  • Arizona Arthritis & Rheumatology Research, PLLC

    Paradise Valley, Arizona, 85253

  • Philip Blum

    Pasadena, Texas, 77504

  • New Jersey Physicians, LLC

    Passaic, New Jersey, 07055

  • Pearland Primary Care Associates

    Pearland, Texas, 77584

  • Southwest Clinical Research Centers, LLC

    Pearland, Texas, 77584

  • University Clinical Research

    Pembroke Pines, Florida, 33024

  • Pembroke Clinical Trials

    Pemkbroke Pines, Florida, 33028

  • Pivotal Research Centers

    Peoria, Arizona, 85381

  • Elite Clinical Studies, LLC

    Phoenix, Arizona, 85018

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Phoenix, Arizona, 85037

  • Highland Community Hospital

    Picayune, Mississippi, 39466

  • Mississippi Medical Research

    Picayune, Mississippi, 39466

  • Advent Clinical Research Center Inc

    Pinellas Park, Florida, 33781

  • Advent Clinical Research Centers

    Pinellas Park, Florida, 33781

  • Clinical Trials Research Services, LLC

    Pittsburgh, Pennsylvania, 15206

  • Berkshire Rheumatology

    Pittsfield, Massachusetts, 01201

  • Prem C. Chatpar, MD, LLC

    Plainview, New York, 11803

  • Plano Primary Care Clinic

    Plano, Texas, 75075

  • Advanced Family Medical Care

    Plano, Texas, 75093

  • Berma Research Group

    Plantation, Florida, 33324

  • Accord Clinical Research, LLC

    Port Orange, Florida, 32129

  • Doris M. Rice, M.D., F.A.C.R.

    Portsmouth, Virginia, 23701

  • Wake Internal Medicine Consultants Inc

    Raleigh, North Carolina, 27612

  • Wake Research Associates

    Raleigh, North Carolina, 27612

  • Advances in Medicine

    Rancho Mirage, California, 92270

  • Regional Health Clinical Research

    Rapid City, South Dakota, 57701

  • Regional Medical Clinical-Rheumatology

    Rapid City, South Dakota, 57701

  • National Clinical Research Richmond Inc.

    Richmond, Virginia, 23294

  • Hypothe Test, LLC

    Roanoke, Virginia, 24018

  • The Carolina Center for Rheumatology and Arthritis Care, PA

    Rock Hill, South Carolina, 29732

  • Rockford Orthopedic Associates

    Rockford, Illinois, 61107

  • ACCR/Internal Medicine

    Roswell, Georgia, 30075

  • Mercy Imaging Center

    Sacramento, California, 95823

  • Northern Clinical Research

    Sacramento, California, 95831

  • Crescent Medical Research

    Salisbury, North Carolina, 28144

  • Optimum Clinical Research, Inc.

    Salt Lake City, Utah, 84102

  • Radiant Research, Inc.

    Salt Lake City, Utah, 84107

  • Alamo Clinical Research Associates

    San Antonio, Texas, 78212

  • Alamo Clinical Research Consultants

    San Antonio, Texas, 78212

  • Texas Arthritis Research Center, PA

    San Antonio, Texas, 78217

  • Clinical Trials of Texas, Inc.

    San Antonio, Texas, 78229

  • Innovative Clinical Trials

    San Antonio, Texas, 78229

  • Radiant Research San Antonio

    San Antonio, Texas, 78229

  • SAM Clinical Research Center

    San Antonio, Texas, 78229

  • San Antonio Preventive & Diagnostic Medicine, PA

    San Antonio, Texas, 78229

  • South Texas Radiology Imaging Center

    San Antonio, Texas, 78229

  • The Rehab Group

    San Antonio, Texas, 78229

  • California Research Foundation

    San Diego, California, 92103-6204

  • San Diego Arthritis Medical Clinic

    San Diego, California, 92108

  • Kaiser Permanente Medical Center

    San Francisco, California, 94118

  • eStudySite

    San Jose, California, 95124

  • Trinity Clinical Trials

    Santa Ana, California, 92701

  • Apex Research Institute

    Santa Ana, California, 92705

  • HeartCare Research

    Sarasota, Florida, 34232

  • Kennedy-White Orthopaedic Center

    Sarasota, Florida, 34232

  • Sarasota Center for Clinical Research

    Sarasota, Florida, 34232

  • Lovelace Scientific Resources

    Sarasota, Florida, 34233

  • The Arthritis Specialty Centre

    Sarasota, Florida, 34233

  • Cochise Clinical Research

    Sierra Vista, Arizona, 85635

  • Springfield Clinic

    Springfield, Illinois, 62702

  • Springfield Clinical Research Department

    Springfield, Illinois, 62703

  • Medex Healthcare Research, Inc.

    St Louis, Missouri, 63117

  • Rheumatology and Internal Medicine Associates of West County, P.C.

    St Louis, Missouri, 63131

  • A & A Pain Institute

    St Louis, Missouri, 63141

  • Arthritis Consultants Inc.

    St Louis, Missouri, 63141

  • Dale G. Bramlet, MD, P.L.

    St. Petersburg, Florida, 33713

  • St. Joseph Medical Associates

    Stockton, California, 95204

  • Sugar Land Med-Ped, PA

    Sugar Land, Texas, 77479

  • Tacoma Center for Arthritis Research, PS

    Tacoma, Washington, 98405-2308

  • Soutwest Florida Clinical Research Center

    Tampa, Florida, 33609-3018

  • Stedman Clinical Trials

    Tampa, Florida, 33613

  • Tampa Medical Group, PA

    Tampa, Florida, 33614

  • Rheumatology Associates of North Jersey

    Teaneck, New Jersey, 07666

  • Premiere Phamaceutical Research, LLC

    Tempe, Arizona, 85282

  • Scott & White Healthcare

    Temple, Texas, 76508

  • SPRI Bronx LLC

    The Bronx, New York, 10454

  • Martin Diagnostic Clinic

    Tomball, Texas, 77375

  • Arthritis & Osteoporosis Associates

    Toms River, New Jersey, 08757

  • Medical Research Associates

    Traverse City, Michigan, 49684

  • Premier Research

    Trenton, New Jersey, 08611

  • New England Research Associates, LLC

    Trumbull, Connecticut, 06611

  • Radiant Research

    Tucson, Arizona, 85710

  • Arizona Research Associates

    Tucson, Arizona, 85712-2142

  • Quality of Life Medical and Research Center

    Tucson, Arizona, 85712

  • Tucson Orthopaedic Institute

    Tucson, Arizona, 85712

  • Rheumatology Associates Inc

    Tulsa, Oklahoma, 74136

  • Deerbrook Medical Associates

    Vernon Hills, Illinois, 60061

  • Arthritis, Rheumatic & Back Disease Associates

    Voorhees Township, New Jersey, 08043

  • Omega Medical Research

    Warwick, Rhode Island, 02886

  • MedVadis Research Corporation

    Watertown, Massachusetts, 02472

  • Integrated Clinical Trial Services, Inc

    West Des Moines, Iowa, 50265

  • Southgate Medical Group

    West Seneca, New York, 14224

  • Westlake Medical Center

    Westlake Village, California, 91361

  • Aquilo Clinical Research

    Yukon, Oklahoma, 73099

  • Florida Medical Clinic, PA

    Zephyrhills, Florida, 33542

Other trials in United States

South Africa14 sites
  • Tiervlei Trial Center

    Bellville

  • Worthwhile Clinical Trials

    Benoni, 1500

  • Josha Research

    Bloemfontein, 9301

  • Vincent Pallotti Hospital

    Cape Town, 7405

  • Private Practice

    Durban, 4091

  • Randles Road Medical Center

    Durban, 4091

  • A. Briel

    Durbanville, 7550

  • Origin Clinical Research

    Johannesburg, 2060

  • Clinresco Centres (Pty) Ltd

    Kempton Park, 1619

  • Phelang Private Hospital Research Unit

    Mamelodi East, Pretoria, 0122

  • Paarl Research Center

    Paarl, 7646

  • 136 Panorama Medical Center

    Panorama, CAPE TOWN, 7500

  • TREAD Research

    Parrowvalley, 7500

  • Clinical Research Unit

    Pretoria, 0083

Other trials in South Africa

Canada12 sites
  • MAC Research Inc.

    Hamilton, Ontario, L8N 2B6

  • KW Musculoskeletal Research Inc.

    Kitchener, Ontario, N2M 5N6

  • Office of Diane Wilson

    Lunenburg, Nova Scotia, B0J 2C0

  • The Arthritis Program Research Group

    Newmarket, Ontario, L3Y 3R7

  • SKDS Research Inc.

    Newmarket, Ontario, L3Y 5G8

  • Groupe de Recherche en Rhumatologie et Maladies Osseuses

    Québec, Quebec, G1V 3M7

  • Clinique Medicale St-Louis

    Québec, Quebec, G1W 4R4

  • Polyclinique St. Eustache

    Saint-Eustache, Quebec, J7P 4J2

  • Diex Research Sherbrooke Inc.

    Sherbrooke, Quebec, J1H 1Z1

  • Dr. Saeed Shaikh

    St. Catharines, Ontario, L2N 7E4

  • Dr. Anil Gupta

    Toronto, Ontario, M9V 4B4

  • Centre de Recherche Musculo-Squelettique

    Trois-Rivières, Quebec, G8Z 1Y2

Other trials in Canada

Spain9 sites
  • Complejo Hospitalario Universitario de A Coruna

    A Coruña, 15006

  • Hospital de Cruces, Servicio de Reumatologia

    Barakaldo (Vizcaya), 48903

  • Clinica CIMA

    Barcelona, 08034

  • Servicio de Reumatologia,Institut Ferran de Reumatologia-Clinica CIMA

    Barcelona, 08034

  • Hospital El Tomillar

    Dos Hermanas, Sevilla, 41700

  • Hospital Universitario La Paz, Servicio de Reumatologia

    Madrid, 28046

  • Corporacio Sanitaria Parc Tauli de Sabadell, Servicio de Reumatologia

    Sabadell, Barcelona, 08208

  • Hospital Nuestra Senora de la Esperanza, Servicio de Reumatologia

    Santiago de Compostela, A Coruna, 15705

  • Hospital Nuestra Senora de Valme, Servicio de Reumatologia

    Seville, 41014

Other trials in Spain

India8 sites
  • St. Johns Medical College Hospital, Department of Orthopaedics

    Bangalore, Karnataka, 560034

  • M.S. Ramaiah Memorial Hospital, Department of Orthopaedics

    Bangalore, Karnataka, 560054

  • ChanRe Rheumatology & Immunology Center & Research

    Bangalore, Karnataka, 560079

  • PSG Institute of Medical Sciences and Research

    Coimbatore, Tamil Nadu, 641004

  • CSM Medical University, Department of Rheumatology

    Lucknow, Uttar Pradesh, 226018

  • KMC Hospital, Department of Orthopaedics

    Mangalore, Karnataka, 575 001

  • Sancheti Hospital

    Pune, Maharashtra, 411 005

  • Krishna Institute of Medical Sciences Ltd., Department of Rheumatology

    Secunderabad, Andhra Pradesh, 500003

Other trials in India

Philippines8 sites
  • Cebu Orthopedic Institute

    Cebu City, 6000

  • Chong Hua Hospital, Medical Arts Center

    Cebu City, 6000

  • Diaz Building

    Cebu City, 6000

  • Asian Hospital and Medical Center

    City of Muntinlupa, 1780

  • Davao Doctors Hospital, Medical Tower

    Davao City, 8000

  • Davao Doctors Hospital

    Davao City, 8000

  • Rayuma Clinic, OPD , Jose Reyes Memorial Medical Center

    Manila, 1003

  • Chinese General Hospital and Medical Center, Out Patient Department

    Manila

Other trials in Philippines

Ukraine8 sites
  • Chernivtsi Regional Clinical Hospital

    Chernivtsi, 58002

  • City Clinical Hospital #5

    Donetsk, 83000

  • V.K. Gusak Institute of Urgent and Recovery Surgery

    Donetsk, 83045

  • Kiev City Oleksandrivska Clinical Hospital

    Kiev, 01601

  • Kiev City Clinical Hospital #3

    Kiev, 02125

  • State Institution "Research Centre for Radiation Medicine AMS of Ukraine"

    Kiev, 03115

  • State Institution "Institute of Gerontology AMS of Ukraine"

    Kiev, 04114

  • Municipal institution :Zaporizhzhya Regional Clinical Hospital

    Zaporizhzhya, 69600

Other trials in Ukraine

Russia6 sites
  • State Healthcare Institution Moscow City Clinical Hospital #4

    Moscow, 115093

  • State Healthcare Institution: Moscow City Clinical Hospital #7

    Moscow, 115446

  • Institution Of Russian Academy of Medical Sciences

    Moscow, 115522

  • Federal State Healthcare Institution Clinical Hospital #122 n.a.Sokolov

    Saint Petersburg, 194291

  • Saint-Petersburg State Healthcare Institution "City Hospital #26"

    Saint Petersburg, 196247

  • Saint Petersburg State Medical University named after Pavlov

    Saint Petersburg, 197022

Other trials in Russia

Colombia5 sites
  • Centro Integral de Reumatologia e Inmunologia CIREI

    Bogota, Cundinamarca

  • Riesgo de Fractura S.A.

    Bogota-Cundinamarca

  • Hospital Pablo Tobon Uribe

    Medellín, Antioquia

  • Clinica Las Americas

    Medellín

  • Reumatologya S.A.

    Medellín

Other trials in Colombia

Mexico5 sites
  • Unidad de Enfermedades Reumaticas y Cronico Degenerativas S.C.

    Coahuila, 27000

  • Hospital General de Culiacan, S.S., "Dr. Bernardo Gastelum".

    Culiacan Sinaloa, CP 80230

  • URHIA(Unidad de Investigacion en Reumatologia)Hospital Civil de Guadalajara"Fray Antonio Alcalde"

    Guadalajara, Jalisco, CP 44280

  • Hospital Aranda de la Parra

    Leon Gto, C.P. 37000

  • Beneficencia Espanola de la Laguna

    Torreon Coahuila, CP 27000

Other trials in Mexico

South Korea5 sites
  • Kyungpook National University Hospital

    Daegu, 700-721

  • Inha University Hospital

    Incheon, 400-711

  • Seoul National University Hospital

    Seoul, 110-744

  • Hanyang University Hospital

    Seoul, 133-792

  • The Catholic University of Korea, Seoul St.Mary's Hospital

    Seoul, 137-701

Other trials in South Korea

Netherlands3 sites
  • READE

    Amsterdam, 1056 AB

  • UMC St. Radboud

    Nijmegen, 6525 GA

  • UMC Utrecht

    Utrecht, 3584 CX

Other trials in Netherlands

About this study

Official title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF THE LONG-TERM ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ALONE OR IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) VERSUS NSAIDS ALONE IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP

The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy.

Read the detailed description

This study was terminated on 28 October 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.

Being tested
NSAID, tanezumab
Keywords
monoclonal antibody, nerve growth factor (NGF), anti-NGF, tanezumab, PF-04383119, RN624, osteoarthritis (OA)
Medical subject headings
Osteoarthritis, Arthritis, Hereditary Sensory and Autonomic Neuropathies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NSAIDDrug

    IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks

  • tanezumabBiological

    IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56

  • tanezumabBiological

    IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56

  • tanezumabBiological

    IV tanezumab 5 mg every 8 weeks (through Week 48)

  • NSAIDDrug

    Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks

  • tanezumabBiological

    IV tanezumab 10 mg every 8 weeks (through Week 48)

  • NSAIDDrug

    Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks

Study groups in NCT00809354
Study groupRoleWhat they receive
IV Placebo + NSAIDActive comparatorOral NSAID
Receives: Drug: NSAID
Tanezumab 5 mgExperimentalIV tanezumab 5 mg every 8 weeks (through Week 48)
Receives: Biological: tanezumab
Tanezumab 10 mgExperimentalIV tanezumab 10 mg every 8 weeks (through Week 48)
Receives: Biological: tanezumab
Tanezumab 5 mg + NSAIDExperimentalIV doses of tanezumab 5 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
Receives: Biological: tanezumab; Drug: NSAID
Tanezumab 10 mg + NSAIDExperimentalIV doses of tanezumab 10 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
Receives: Biological: tanezumab; Drug: NSAID

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

    Measured: Baseline, Week 16

  2. Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip).The WOMAC physical function subscale was comprised of 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Physical function refers to participant's ability to move around and perform usual activities of daily living.

    Measured: Baseline, Week 16

  3. Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Week 16

    Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition.

    Measured: Baseline, Week 16

Secondary outcomes (44)
  1. Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

    Measured: Baseline, Weeks 2, 4, 8, 12, and 24

  2. Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

  3. Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip).The WOMAC physical function subscale was comprised of 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Physical function refers to participant's ability to move around and perform usual activities of daily living.

    Measured: Baseline, Weeks 2, 4, 8, 12, and 24

  4. Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip).The WOMAC physical function subscale was comprised of 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Physical function refers to participant's ability to move around and perform usual activities of daily living.

    Measured: Baseline, Weeks 2, 4, 8, 12, 24, 32, 40, 48, and 56

  5. Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)

    Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= mild symptoms and no limitation of normal activities, 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (Very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition.

    Measured: Baseline, Weeks 2, 4, 8, 12, and 24

  6. Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

    Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= mild symptoms and no limitation of normal activities, 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (Very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

  7. Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response: Baseline Observation Carried Forward (BOCF)

    Participants were considered as OMERACT-OARSI responder: if the improvement from baseline to week of interest was greater than or equal to (>=) 50 percent and >=2 units in WOMAC pain subscale or WOMAC physical function subscale score, or at least 2 of the following 3 being true: improvement from baseline to week of interest was >=20 percent and >=1 unit in 1) WOMAC pain subscale score, 2) WOMAC physical function subscale score, 3) PGA of osteoarthritis. WOMAC pain subscale assess amount of pain experienced (score: 0 [no pain] to 10 [worst possible pain], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 [minimum difficulty] to 10 [maximum difficulty], higher score = worse physical function) and PGA of osteoarthritis (score: 1 [very good] to 5 [very poor], higher score = worse condition).

    Measured: Weeks 2, 4, 8, 12, 16, and 24

  8. Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response: Last Observation Carried Forward (LOCF)

    Participants were considered as OMERACT-OARSI responder: if the improvement from baseline to week of interest was >=50 percent and >=2 units in WOMAC pain subscale or WOMAC physical function subscale score, or at least 2 of the following 3 being true: improvement from baseline to week of interest was >=20 percent and >=1 unit in 1) WOMAC pain subscale score, 2) WOMAC physical function subscale score, 3) PGA of osteoarthritis. WOMAC pain subscale assess amount of pain experienced (score: 0 [no pain] to 10 [worst possible pain], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 [minimum difficulty] to 10 [maximum difficulty], higher score = worse physical function) and PGA of osteoarthritis (score: 1 [very good] to 5 [very poor], higher score = worse condition).

    Measured: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

  9. Percentage of Participants With at Least 30 Percent (%), 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score From Baseline at Weeks 2, 4, 8, 12, 16, and 24: BOCF

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Percentage of participants who experienced an improvement (reduction) of >=30%, >=50%, >=70%, or >=90% in the WOMAC pain subscale scores from Baseline were reported.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, and 24

  10. Percentage of Participants With at Least 30%, 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Percentage of participants who experienced an improvement (reduction) of >=30 percent, >=50%, >=70%, or >=90% in the WOMAC pain subscale scores from Baseline were reported.

    Measured: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

  11. Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Number of participants who experienced reduction (as percent) of >0% to >=100% from Baseline in WOMAC pain subscale scores at Week 16 were reported.

    Measured: Baseline, Week 16

  12. Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Number of participants who experienced reduction (as percent) of >0% to >=100% from Baseline in WOMAC pain subscale scores at Week 16 were reported.

    Measured: Baseline, Week 16

  13. Percentage of Participants With Improvement of At Least 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, and 24: Baseline Observation Carried Forward (BOCF)

    Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= mild symptoms and no limitation of normal activities, 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (Very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value. Percentage of participants who showed an improvement of >=2 points on scale were reported.

    Measured: Weeks 2, 4, 8, 12, 16, and 24

  14. Percentage of Participants With Improvement of Atleast 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56: Last Observation Carried Forward (LOCF)

    Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= mild symptoms and no limitation of normal activities, 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (Very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value. Percentage of participants who showed an improvement of >=2 points on scale were reported.

    Measured: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

  15. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC stiffness subscale was a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis of the index joint (knee or hip) during the past 48 hours. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). It was calculated as mean of the scores from 2 individual questions scored on NRS of 0 (no stiffness) to 10 (worst stiffness), with higher scores indicate more stiffness. Total score range for WOMAC stiffness subscale score was 0 (no stiffness) to 10 (worst stiffness), where higher scores indicated more stiffness.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, and 24

  16. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC stiffness subscale was a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in the index joint (knee or hip) during the past 48 hours. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). It was calculated as mean of the scores from 2 individual questions scored on NRS of 0 (no stiffness) to 10 (worst stiffness), with higher scores indicate more stiffness. Total score range for WOMAC stiffness subscale score was 0 (no stiffness) to 10 (worst stiffness), where higher scores indicated more stiffness.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

  17. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). Each item is scored on a 0 to 10 NRS scale, where higher scores indicate higher pain/stiffness or worse function. WOMAC average score was calculated as the mean of 3 WOMAC subscale scores (pain, physical function and stiffness). Total score range was 0 (no response) to 10 (worse response), where higher score indicated worse response.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, and 24

  18. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). Each item is scored on a 0 to 10 NRS scale, where higher scores indicate higher pain/stiffness or worse function. WOMAC average score was calculated as the mean of 3 WOMAC subscale scores (pain, physical function and stiffness). Total score range was 0 (no response) to 10 (worse response), where higher score indicated worse response.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

  19. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). Participants responded about the amount of pain they experienced when walking on a flat surface by answering the question: "How much pain have you had when walking on a flat surface?". Participants responded by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, and 24

  20. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). Participants responded about the amount of pain they experienced when walking on a flat surface by answering the question: "How much pain have you had when walking on a flat surface?". Participants responded by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

  21. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). Participants responded about the amount of pain they experienced when going up or down stairs by answering the question: "How much pain have you had when going up or down the stairs?" Participants responded by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, and 24

  22. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). Participants responded about the amount of pain they experienced when going up or down stairs by answering the question: "How much pain have you had when going up or down the stairs?" Participants responded by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

  23. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24: Baseline Observation Carried Forward (BOCF)

    The SF-36 health survey is a self-administered questionnaire that measures each of the following 8 health domains: domain 1= general health, domain 2= physical function, domain 3= role physical, domain 4= bodily pain, domain 5= vitality, domain 6= social function, domain 7= role emotional, domain 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher scores represent better health status.

    Measured: Baseline, Weeks 12 and 24

  24. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Weeks 12, 24, 40 and 56: Last Observation Carried Forward (LOCF)

    The SF-36 health survey is a self-administered questionnaire that measures each of the following 8 health domains: domain 1= general health, domain 2= physical function, domain 3= role physical, domain 4= bodily pain, domain 5= vitality, domain 6= social function, domain 7= role emotional, domain 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher scores represent better health status.

    Measured: Baseline, Weeks 12, 24, 40, and 56

  25. Number of Participants Who Had Discontinued Study Due to Lack of Efficacy

    Measured: Baseline up to Week 56

  26. Time to Discontinuation Due to Lack of Efficacy

    Time to discontinuation due to lack of efficacy was defined as the time interval from the date of study drug administration up to the date of discontinuation of participant from study due to lack of efficacy.

    Measured: Baseline up to Week 56

  27. Change From Baseline in Percent Work Time Missed Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)

    The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions (Q) are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent work time missed due to health problem: Q2/(Q2+Q4). The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.

    Measured: Baseline, Week 24

  28. Change From Baseline in Percent Work Time Missed Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)

    The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent work time missed due to health problem: Q2/(Q2+Q4). The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.

    Measured: Baseline, Week 24 and 56

  29. Change From Baseline in Percent Impairment While Working Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)

    The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent impairment while working due to health problem: Q5/10. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.

    Measured: Baseline, Week 24

  30. Change From Baseline in Percent Impairment While Working Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)

    The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent impairment while working due to health problem: Q5/10. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.

    Measured: Baseline, Weeks 24 and 56

  31. Change From Baseline in the Percent Overall Work Impairment Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): BOCF

    The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent overall work impairment due to health problem: Q2/(Q2+Q4)+[(1-Q2/(Q2+Q4))*(Q5/10)]. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.

    Measured: Baseline, Week 24

  32. Change From Baseline in the Percent Overall Work Impairment Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): LOCF

    The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent overall work impairment due to health problem: Q2/(Q2+Q4)+[(1-Q2/(Q2+Q4))*(Q5/10)]. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.

    Measured: Baseline, Weeks 24 and 56

  33. Change From Baseline in the Percent Activity Impairment Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)

    The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent activity impairment due to health problem: Q6/10. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.

    Measured: Baseline, Week 24

  34. Change From Baseline in the Percent Activity Impairment Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)

    The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent activity impairment due to health problem: Q6/10. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.

    Measured: Baseline, Weeks 24, and 56

  35. Percentage of Participants Who Used Rescue Medication: Observed Data

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day for maximum of 3 days within a week could be taken as rescue medication. Percentage of participants with any use of rescue medication during each study interval were summarized.

    Measured: Weeks 1-2, 3-4, 5-8, 9-12, 13-16, 17-24, 25-32, 33-40, 41-48 and 49-56

  36. Percentage of Participants Who Used Rescue Medication: Last Observation Carried Forward (LOCF)

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day for maximum of 3 days within a week could be taken as rescue medication. Percentage of participants with any use of rescue medication during each study interval were summarized.

    Measured: Weeks 1-2, 3-4, 5-8, 9-12, 13-16, 17-24, 25-32, 33-40, 41-48 and 49-56

  37. Amount of Rescue Medication Used

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days in a week could be taken as rescue medication. The total dosage of acetaminophen in mg used during the specified time intervals were summarized.

    Measured: Weeks 1-2, 3-4, 5-8, 9-12, 13-16, 17-24, 25-32, 33-40, 41-48, and 49-56

  38. Change From Baseline in Medial Minimum Joint Space Width of the Index Knee at Week 56

    Measured: Baseline, Week 56

  39. Change From Baseline in Minimum Joint Space Width of the Index Hip at Week 56

    Measured: Baseline, Week 56

  40. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 64 that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.

    Measured: Baseline up to Week 64

  41. Change From Baseline in Neuropathy Impairment Score (NIS) at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Observed Data

    The Neuropathy Impairment Score is the sum of scores over all 37 items from both the left and right side. The neurological impairment score assessed strength of groups of muscles of the head and neck, upper limbs and lower limbs, deep tendon reflexes and sensation (tactile, vibration, joint position sense, and pin prick) of index fingers and great toes through neurological examination. NIS calculated scoring muscle weakness (0=normal, 1=25% weak, 2=50% weak, 3=75% week, 3.25= move against gravity, 3.5=movement gravity eliminated, 3.75= muscle flicker no movement, 4=paralysis), scoring reflexes (0=normal, 1=reduced. 2=absent), scoring sensation (0=normal, 1=decreased, 2=absent). For NIS possible overall score (combined of both left and right sides of each domain), ranged from 0 (no impairment) to 244 (maximum impairment), higher scores indicated increased/more neuropathic deficits.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56

  42. Change From Baseline in Neuropathy Impairment Score (NIS) at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)

    The Neuropathy Impairment Score is the sum of scores over all 37 items from both the left and right side. The neurological impairment score assessed strength of groups of muscles of the head and neck, upper limbs and lower limbs, deep tendon reflexes and sensation (tactile, vibration, joint position sense, and pin prick) of index fingers and great toes through neurological examination. NIS calculated scoring muscle weakness (0=normal, 1=25% weak, 2=50% weak, 3=75% week, 3.25= move against gravity, 3.5=movement gravity eliminated, 3.75= muscle flicker no movement, 4=paralysis), scoring reflexes (0=normal, 1=reduced. 2=absent), scoring sensation (0=normal, 1=decreased, 2=absent). For NIS possible overall score (combined of both left and right sides of each domain), ranged from 0 (no impairment) to 244 (maximum impairment), higher scores indicated increased/more neuropathic deficits.

    Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56

  43. Plasma Trough (Pre-dose) Concentration of Tanezumab

    Measured: Predose on Day 1, Weeks 16, 24, 40, and 56

  44. Number of Participants With Intravenous (IV) Doses of Study Medication

    Number of participants are reported based on the maximum number of IV doses of either tanezumab or placebo received.

    Measured: Baseline up to Week 48

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Dec 2008 (estimated)
  2. Study start12 Feb 2009
  3. Primary completion28 Oct 2010
  4. Study completion12 Jan 2011

Why it stopped: See termination reason in detailed description.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
2,720 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00809354
Sponsor's protocol ID
A4091025
Other IDs
2008-004815-37, OA CONTROLLED SAFETY STUDY, 2008
Status last verified
Jun 2021
First submitted
16 Dec 2008
Last updated
24 Jun 2021
Data monitoring committee
Yes
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Publications

  • Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019 Mar 19;12:975-995. doi: 10.2147/JPR.S191297. eCollection 2019.

    PubMed 30936738
  • Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, Smith MD, Hungerford DS. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. Arthritis Rheumatol. 2016 Feb;68(2):382-91. doi: 10.1002/art.39492.

    PubMed 26554876
  • Schnitzer TJ, Ekman EF, Spierings EL, Greenberg HS, Smith MD, Brown MT, West CR, Verburg KM. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis. 2015 Jun;74(6):1202-11. doi: 10.1136/annrheumdis-2013-204905. Epub 2014 Mar 13.

    PubMed 24625625

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing NSAID and tanezumab in people with Osteoarthritis and Arthritis, run by Pfizer at 333 sites in 12 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 24 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 333 sites in United States, South Africa, Canada, Spain, India and 7 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 24 Jun 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16 (time frame: Baseline, Week 16). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00809354, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in